A multinаtiоnаl spоnsоr is prepаring to initiate a clinical trial at several South African research sites. During the start-up process, the sponsor ensures that the protocol complies with ICH E6 GCP requirements relating to investigator responsibilities, sponsor oversight, and ethics committee review. Which of the following best explains the difference between the regulatory and oversight structures described in ICH E6 GCP and SA GCP 2020?